Clinical Trials Appendix

Q3 2024 Results Update

November 12, 2024

Disclosures

Certain statements contained in this presentation and in any accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding the projected dates for upcoming regulatory approvals; and BeiGene's research, discovery, and pre-clinical and early-stage clinical programs and plans. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and medicines; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent periodic report filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All information in this presentation is as of the date of this presentation, and BeiGene undertakes no duty to update such information unless required by law.

Our Pipeline Snapshot

Across three therapy areas:





140+

Clinical studies run by BeiGene

40+

Clinical and commercial stage assets

24,000+

Patients enrolled in clinical trials globally*

70+

Approvals for BRUKINSA® (zanubrutinib) globally

* Includes investigator initiated trials (IITs)

BeiGene: Key Upcoming Regulatory Action Catalysts 2H, 2024-2025

Potential Approvals



2H, 2024

Q4

BRUKINSA – 302/304/305 WM and CLL/SLL **JP**

BRUKINSA – additional ~14 global approvals

TEVIMBRA – 306 1L ESCC **US***

TEVIMBRA – 305 1L GC **US**

TEVIMBRA – 306 1L ESCC **AU**

TEVIMBRA – additional ~5 global approvals

1H, 2025

BRUKINSA – 206 R/R MCL **UK**

BRUKINSA – 114 Tablet formulation **US, CA, AU**

BRUKINSA – additional ~10 global approvals

TEVIMBRA – 302 2L ESCC Q2W, Q4W **US**

TEVIMBRA – 302 2L ESCC **JP**

TEVIMBRA – 305 1L GC **EU, AU**

TEVIMBRA – 306 1L ESCC **EU, JP**

TEVIMBRA – additional 21 global approvals

2H, 2025

BRUKINSA – 114 Tablet formulation **EU**

BRUKINSA – 212/305 R/R FL and CLL **BR**

BRUKINSA – additional ~11 global approvals

TEVIMBRA – 302 2L ESCC Q6W **US**

TEVIMBRA – 305 1L GC **BR**

TEVIMBRA – 305 1L GC Q2W, Q4W, Q6W **US**

TEVIMBRA – 306 1L ESCC **BR**

TEVIMBRA – 306 1L ESCC Q2W, Q4W **US**

TEVIMBRA – 309 1L NPC **EU, AU**

TEVIMBRA – 312 1L ES-SCLC **EU**

TEVIMBRA – 315 Neo/adj NSCLC **EU**

TEVIMBRA – Q2W, Q4W **AU**

TEVIMBRA – additional ~34 global approvals

Zanidatamab- 203**,** 2L BTC, **CN**

* Due to a delay in scheduling clinical inspections, the target PDUFA date of July 2024 was deferred

BR - Brazil; CN - China; AU – Australia; JP - Japan; UK – United Kingdom; CA – Canada; EU – European Union

Refer to Glossary for other abbreviations

BeiGene: Project Movements Since Q2 2024 Update

New to Phase 1/1b

BGB-B2033-101
(GPC3x4-1BB BsAb)

BGB-B3227-101
(MUC1xCD16A BsAb)

BG-C477-101
(CEA ADC)

BG-T187-101
(EGFRxMET Ts Ab)

BG-C137-101
(FGFR2B ADC)†

BGB-53038-101
(Pan-KRASi)†

BGB-58067-101
(PRMT5i)†

BGB-16673-104
(BTK CDAC)†

New to Phase II

BGB-11417-204
(BCL2)†

New to Pivotal Trial

New Submission

Tislelizumab 302
(2L ESCC Q2W) in US

Tislelizumab 303, 304, 307
(1L/2L NSCLC) in IL

Tislelizumab 305
(1L GC) in BR, SG

Tislelizumab 306
(1L ESCC) in BR, SG

Tislelizumab 309
(1L NPC) in EU, KR, SG

Tislelizumab 312 1L
(ES-SCLC) in EU

Zanubrutinib 114
(Tablet formulation) in US

Zanubrutinib 212
(R/R FL) in IL

Zanubrutinib 206, 212, 214, 302, 305
(R/R CLL, R/R MCL, R/R FL, R/R MZL, TN WM) in IN

Approved

Tislelizumab 302
(2L ESCC) in BR, SG, IL, TH

Tislelizumab 303
(2L NSCLC) in BR, SG,TH

Tislelizumab 304 / 307
(1L NSCLC) in TH

Tislelizumab 305
(1L GC) in TH

Tislelizumab 306
(1L ESCC) in TH

Tislelizumab 315
(Neo/adj NSCLC) in CN

Zanubrutinib 212
(R/R FL) in AR, HK, MO, KR, RS

Zanubrutinib 214
(R/R MZL) in PH, RS

Zanubrutinib 304, 305
(R/R & TN CLL) in AR, HK, RS (R/R CLL) in PH

BR - Brazil; CN - China; AR - Argentina; IL - Israel; IN - India; SG - Singapore; TH – Thailand; KR – South Korea; PH – Philippines; HK – Hong Kong; MO – Macao; RS - Serbia

Refer to Glossary for other abbreviations

† Trial is listed on clinicaltrials.gov but may not have subjects enrolled.

Innovative Solid Tumor NME Early Pipeline

Differentiated molecules with multiple modalities in priority tumor types

Lung

- PanKRASi
- MTA Cooperative PRMT5i
- SMAC Mimetic*
- CEA ADC*
- B7H3 ADC*
- EGFR CDAC
- EGFR x MET Tsp*

Breast/Gynecologic

- CDK4i*
- CDK2i*
- Next-gen BCL2i*
- SMAC Mimetic*
- B7H4 ADC*
- Claudin6 x CD3

GI

- PanKRASi
- FGFR2b ADC
- CEA ADC*
- GPC3 x 4-1BB*
- MUC1 x CD16A*

Pan-Tumor

- DGKζi*
- HPK1i*
- CCR8*
- IL-15 prodrug*

Small molecule | Protein degrader | Bi/Tri-specific | mAb | ADC | Cytokine therapy

BeiGene has global rights for CDK2 (Ensem partnership) and B7H4 ADC (DualityBio partnership)
* In the clinic

BeiGene: Building Leadership in Solid Tumors With Innovative NMEs

	Pre-Clinical	Phase 1		Phase 2		Phase 3	
Breast/ Gynecologic Cancers	**BGB-B455** **Claudin6xCD3** Gyn (other ST)	**BGB-C9074-101** **B7H4-ADC** Breast (other ST)	**BGB-43395-101/102** **CDK4i** Breast (other ST)				
	BGB-21447* **BCL2i** Breast (other ST)	**BG-68501-101 CDK2i** Breast (other ST)	**BGB-24714-101** **SMAC** Solid Tumors				
Gastro-intestinal			**BGB-B2033-101** **GPC3x4-1BB** Solid Tumors	**BG-C137-101** † **FGFR2b ADC** GI	**BGB-LBL-007-201** **LAG-3** MSS-CRC	**BGB-LBL-007-202** **LAG-3** 1L ESCC	**ZWI-ZW25-301** **Zanidatamab HER2** 1L HER2+ GEA
		BG-53038-101 † **Pan-KRASi** GI and lung	**BG-C477-101** **CEA ADC** GI and Lung	**BGB-B3227-101** **MUC1xCD16A** Lung and GI	**ZWI-ZW25-203** **Zanidatamab HER2** 2L+ BTC		
Lung		**BGB-900-105** **Ociperlimab TIGIT** (+Tisle dose finding)	**BGB-C354-101** **B7H3 ADC** Lung, GI and HNSCC	**BG-T187** **EGFRxMET Tsp** Lung and GI	**BGB-LC-201** **Umbrella** 1L NSCLC	**BGB-LC-202** **Umbrella** Neoadjuvant NSCLC	**AdvanTIG-302** **Ociperlimab TIGIT** 1L NSCLC (PDL1 high) / **AMG757 20200041** **Tarlatamab DLL3xCD3** 1L ES-SCLC (CN)
	BG-60366-101 **EGFR-CDAC 2G** Lung		**BGB-58067-101** † **MTA-coop PRMT5i** Lung and GI		**BGB-LC-203** **Umbrella** 2L+ NSCLC	**AMG757 20230273** **Tarlatamab DLL3xCD3** 3L SCLC (CN)	**AMG757 20210004** **Tarlatamab DLL3xCD3** 2L SCLC (CN) / **AMG757 20230016** **Tarlatamab DLL3xCD3** LS-SCLC (CN)
Pan-tumor /Other		**BGB-30813-101** **DGKζ** Solid Tumors	**BGB-A3055-101** **CCR8** Solid Tumors	**BGB-R046-101** **Pro-IL15** Solid Tumors	**BGB-HNSCC-201** **Umbrella** 1L HNSCC	**BGB-A317-A445-201** **BGB-A445 OX40** Melanoma and UC	
		BGB-15025-101 **HPK1** Solid Tumors	**BGB-26808-101** **HPK1 2G** Solid Tumors	**AMG509 20180146** **XaluritamigSTEAP1xCD3** mCRPC (CN)			

Refer to Glossary abbreviations

† Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

* In Ph1 in Heme indications.

BeiGene: Building Leadership in Solid Tumors With LCM

	Phase 1	Phase 2	Phase 3	Approved		
Breast/ Gynecologic Cancers			**BGB-290-302** **Pamiparib PARPi** 2L+ MTx OC	**BGB-290-102** **Pamiparib PARPi** 2L+ gBRCAm OC	**Baituowei (Goserelin)** Breast, Prostate	
Gastro-intestinal		**BGB-A317-209** **Tislelizumab PD-1** Resect MSI-H/ dMMR CRC	**BGB-A317-213** **Tislelizumab PD-1** neo-adj ESCC	**BGB-A317-311** **Tislelizumab PD-1** localized ESCC	**BGB-A317-301** **Tislelizumab PD-1** 1L HCC	**BGB-A317-302** **Tislelizumab PD-1** 2L ESCC
				BGB-A317-306 **Tislelizumab PD-1** 1L ESCC	**BGB-A317-208** **Tislelizumab PD-1** 2L/3L+HCC	
Lung				**BGB-A317-304** **Tislelizumab PD-1** 1L Non-sq. NSCLC	**BGB-A317-307** **Tislelizumab PD-1** 1L Sq. NSCLC	**BGB-A317-303** **Tislelizumab PD-1** 2/3L NSCLC
				BGB-A317-312 **Tislelizumab PD-1** 1L ES-SCLC	**BGB-A317-309** **Tislelizumab PD-1** 1L NPC	**BGB-A317-315** **Tislelizumab PD-1** Neo-adj./adj. NSCLC
Pan tumor /Other	**BGB-A317-103** **Tislelizumab PD-1** Subcutaneous		**BGB-A317-310** **Tislelizumab PD-1** 1L UBC	**BGB-A317-204** **Tislelizumab PD-1** 2L UC	**BGB-A317-209** **Tislelizumab PD-1** Late Line MSI-H or dMMR	
			BGB-A317-290-LTE1 **Multiple BeiGene assets** LTE Solid Tumors			

Refer to Glossary abbreviations

BeiGene: A Leader in Hematology / I&I portfolio – Innovative NMEs

	Phase 1	Phase 2	Phase 3
AML/MDS, Multiple Myeloma, Other Heme	**BGB-11417-103** Sonrotoclax BCL2i AML/MDS **BGB-11417-105** Sonrotoclax BCL2i Multiple Myeloma t(11;14)		
B-Cell	**BGB-21447-101** BCL2i next gen. B-Cell Malignancies **AdvanTIG-101** Ociperlimab TIGIT R/R DLBCL **BGB-11417-102** Sonrotoclax BCL2i B-Cell Malig.(China) **BGB-11417-101** Sonrotoclax BCL2i mono & combo w/ zanu **BGB-16673-101** BTK CDAC B-Cell Malig. **BGB-16673-102** BTK CDAC B-Cell Malig. (China) **BGB-16673-104** BTK CDAC B-Cell Malig. combos	**BGB-16673-101/102** BTK CDAC R/R MCL & R/R CLL **BGB-11417-201** Sonrotoclax BCL2i R/R MCL **BGB-11417-202** Sonrotoclax BCL2i CLL/SLL (China) **BGB-11417-203** Sonrotoclax BCL2i R/R WM **BGB-11417-204** Sonrotoclax BCL2i TN CLL	**BGB-11417-301** Sonrotoclax BCL2i TN CLL combo + zanu
I&I	**BGB-45035-101** IRAK4 CDAC Healthy volunteers		

Refer to Glossary abbreviations

BeiGene: A Leader in Hematology / I&I With LCM

	Phase 1	Phase 2	Phase 3	Approved
AML/MDS, Multiple Myeloma, Other Heme		**BLINCYTO® CD3/CD19 BiTE** Pediatric R/R BP-ALL	**BGB-A317-314 Tislelizumab PD-1** R/R cHL (China)	**BGB-A317-203 Tislelizumab PD-1** R/R cHL
B-Cell		**BGB-3111-215 Zanubrutinib BTKi** Prev. BTKi Tx intolerant **BGB-3111-111 Zanubrutinib BTKi** R/R CLL/SLL, WM, MCL (JP) **BGB-3111-304 Zanubrutinib BTKi** TN CLL Ven combo **BGB-3111-218 Zanubrutinib BTKi** CD79B R/R DLBCL	**BGB-3111-306 Zanubrutinib BTKi** TN MCL **BGB-3111-308 Zanubrutinib BTKi** R/R MZL, R/R FL	**BGB-3111-304 Zanubrutinib BTKi** TN CLL/SLL **BGB-3111-305 Zanubrutinib BTKi** R/R CLL/SLL **BGB-3111-206 Zanubrutinib BTKi** R/R MCL **BGB-3111-214 Zanubrutinib BTKi** R/R MZL **BGB-3111-212 Zanubrutinib BTKi** R/R FL **BGB-3111-302 Zanubrutinib BTKi** TN WM
I&I		**BGB-3111-217 Zanubrutinib BTKi** Lupus Nephritis	**BGB-3111-309 Zanubrutinib BTKi** PMN	

Refer to Glossary abbreviations

Trial detail

- **BRUKINSA®** (zanubrutinib)
- **Sonrotoclax**
- **BGB-16673 BTK CDAC**
- **TEVIMBRA®** (tislelizumab)
- **Other Solid Tumor Assets**

BRUKINSA®

Foundational asset in hematology portfolio

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-3111-111	Phase 2	NCT04172246	B-Cell Malignancies	55		TEAEs and ORR	Maintenance (JP)
BGB-3111-215	Phase 2	NCT04116437	Previous BTKi Tx - ibru/acala intolerant	97		TEAEs	Enrolling
BGB-3111-218	Phase 2	NCT05068440	CD79b R/R DLBCL	66		ORR	Maintenance
BGB-3111-306	Phase 3	NCT04002297	TN MCL	510	Rituximab	PFS	Maintenance
BGB-3111-308	Phase 3	NCT05100862	R/R MZL and FL	788	Rituximab, Obinutuzumab	PFS	Enrolling
BGB-3111-206	Phase 2	NCT03206970	R/R MCL	86		ORR	Approved
BGB-3111-212	Phase 2	NCT03332017	R/R NHL - FL	217	Obinutuzumab	ORR	Approved
BGB-3111-214	Phase 2	NCT03846427	R/R MZL	68		ORR	Approved
BGB-3111-302	Phase 3	NCT03053440	TN & R/R WM	229		CR\VGPR	Approved

Brukinsa® zanubrutinib

Refer to Glossary abbreviations

Sonrotoclax

Potential best-in-class BCL2 inhibitor with differentiated profile

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-11417-101	**Phase 1**	NCT04277637	B-Cell Malignancies	438	Zanubrutinib, Obinutuzumab	TEAEs, MTD	Enrolling
BGB-11417-102	**Phase 1**	NCT04883957	B-Cell Malignancies	64		TEAEs, MTD	Maint. (CN)
BGB-11417-103	**Phase 1**	NCT04771130	AML/MDS	265	Azacitidine	TEAEs, CR, mOR	Enrolling
BGB-11417-105	**Phase 1**	NCT04973605	R/R MM with t(11;14)	181	Dexamethasone, Carfilzomib	TEAEs, ORR, VGPR, CR	Enrolling
BGB-11417-201	**Phase 2**	NCT05471843	Post-BTKi MCL	122		TEAEs, ORR	Maintenance
BGB-11417-202	**Phase 2**	NCT05479994	Post-BTKi CLL/SLL	97		ORR	Maintenance
BGB-11417-203	**Phase 2**	NCT05952037	R/R WM	85	Zanubrutinib	MRR	Enrolling
BGB-11417-204	**Phase 2**	NCT06637501	TN CLL	87	Zanubrutinib	CR/CRi	Active
BGB-11417-301	**Phase 3**	NCT06073821	TN CLL/SLL	640	Zanubrutinib	PFS	Enrolling

Refer to Glossary abbreviations

BGB-16673 BTK CDAC

Potential first-in-class BTK degrader

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-16673-101	**Phase 1/2**	NCT05006716	B-Cell Malignancies	466		TEAEs	Enrolling
BGB-16673-102	**Phase 1**	NCT05294731	B-Cell Malignancies	127		TEAEs, RP2D, ORR	Enrolling
BGB-16673-104	**Phase 1/2**	NCT06634589	B-Cell Malignancies	170	Sonrotoclax, Zanubrutinib	DLTs, TEAEs	Active

Refer to Glossary abbreviations

TEVIMBRA®
Poised for global patient impact

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-LC-201	Phase 2	NCT05635708	1L NSCLC	319	LAG3, OX40, HPK1, Chemotherapy	ORR	Enrolling
BGB-LC-202	Phase 2	NCT05577702	Neo/adj NSCLC	120	LAG3, Chemotherapy	MPR	Enrolling
BGB-A317-310	Phase 3	NCT03967977	1L UBC	436	Chemotherapy	OS (ITT)	Enrolling
BGB-A317-103	Phase 1	NCT06091943	Subcutaneous administration	69		Bioavailability and Safety	Maintenance
BGB-HNSCC-201	Phase 2	NCT05909904	1L HNSCC	160	LAG3, TIM3	ORR	Maintenance
BGB-A317-311	Phase 3	NCT03957590	Localized ESCC	366	Chemotherapy + Radiotherapy	PFS	Maintenance
BGB-A317-213	Phase 2	NCT04974047	Resectable ESCC	70	Chemotherapy + Radiotherapy	pCR rate	Closeout
BGB-A317-312	Phase 3	NCT04005716	1L ES-SCLC	455	Chemotherapy	OS	Approved*
BGB-A317-315	Phase 3	NCT04379635	Neo/adj NSCLC	450	Chemotherapy	MPR, EFS	Approved*
BGB-A317-203	Phase 2	NCT03209973	R/R cHL	68		ORR	Approved*
BGB-A317-204	Phase 2	NCT04004221	2L UC	110		ORR	Approved*

TEVIMBRA (tislelizumab)

* Approved only in China
Refer to Glossary abbreviations

TEVIMBRA®
Poised for global patient impact

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-A317-208	**Phase 2**	NCT03419897	2L+ HCC	250		ORR	Approved*
BGB-A317-209	**Phase 2**	NCT03736889	Late Line MSI-H or dMMR Solid Tumors	150		ORR	Approved*
BGB-A317-301	**Phase 3**	NCT03412773	1L HCC	680		OS	Approved*
BGB-A317-302	**Phase 3**	NCT03430843	2L ESCC	489		OS	Approved
BGB-A317-303	**Phase 3**	NCT03358875	2/3L NSCLC	805		OS (PDL1+), OS	Approved
BGB-A317-304	**Phase 3**	NCT03663205	1L Non-sq. NSCLC	334	Chemotherapy	PFS	Approved
BGB-A317-305	**Phase 3**	NCT03777657	1L GC	978	Chemotherapy	OS	Approved*
BGB-A317-306	**Phase 3**	NCT03783442	1L ESCC	650	Chemotherapy	OS	Approved*
BGB-A317-307	**Phase 3**	NCT03594747	1L Sq. NSCLC	342	Chemotherapy	PFS	Approved
BGB-A317-309	**Phase 3**	NCT03924986	1L NPC	263	Chemotherapy	PFS	Approved*

TEVIMBRA (tislelizumab)

* Approved only in China
Refer to Glossary abbreviations

Phase 1 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-290-102	Pamiparib	PARPi	Ph1	NCT03333915	Ovarian and breast cancer	128		TEAE, SAE, ORR	Approved
BGB-900-105	BGB-A1217	TIGIT	Ph1	NCT04047862	Solid Tumors	476	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Closeout
BGB-24714-101	BGB-24714	SMAC	Ph1	NCT05381909	Solid Tumors	229	Chemotherapy	AE, TEAE, SAE, DLT, MTD, RDFE, ORR	Expansion
BGB-A317-15025-101	BGB-15025	HPK1	Ph1	NCT04649385	Solid Tumors	169	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Expansion
BGB-A317-30813-101	BGB-30813	DGKζ	Ph1	NCT05904496	Solid Tumors	81	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-A317-A3055-101	BGB-A3055	CCR8	Ph1	NCT05935098	Solid Tumors	89	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-C9074-101	BGB-C9074	B7H4 ADC	Ph1	NCT06233942	Solid Tumors	89	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR, RP2D	Dose escalation
BG-68501-101	BG-68501	CDK2i	Ph1	NCT06257264	Solid Tumors	108	BGB-43395, Fulvestrant	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-C354-101	BGB-C354	B7H3 ADC	Ph1	NCT06422520	Solid Tumors	85	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-B2033-101	BGB-B2033	GPC3x4-1BB	Ph1	NCT06427941	Solid Tumors	140	Tislelizumab	AE, SAE, DLT, MTD, RP2D	Dose escalation
BGB-B3227-101	BGB-B3227	MUC1xCD16A	Ph1	NCT06540066	Solid Tumors	75	Tislelizumab, Chemotherapy	AE, SAE, DLT, MTD, RDFE	Dose escalation

Refer to Glossary abbreviations

Phase 1 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-43395-101	BGB-43395	CDK4i	Ph1	NCT06120283	Solid Tumors	225	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-43395-102	BGB-43395	CDK4i	Ph1	NCT06253195	Solid Tumors	78	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-A317-26808-101	BGB-26808	HPK1 2G	Ph1	NCT05981703	Solid Tumors	90	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-R046-101	BGB-R046	IL-15 prodrug	Ph1	NCT06487858	Solid Tumors	74 (CN)	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-C477-101	BG-C477	CEA ADC	Ph1	NCT06596473	Solid Tumors	21	Chemotherapy	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BG-T187-101	BG-T187	EGFRxMET Tsp	Ph1	NCT06598800	Solid Tumors	87		AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
AMG509 20180146	Xaluritamig	STEAP1xCD3	Ph1	NCT04221542	mCRPC	9 (CN)		TEAE, DLTs	Enrolling
BG-C137-101	BG-C137	FGFR2B ADC	Ph1	NCT06625593	Solid Tumors	68		AE, SAE, DLT, MTD, RDFE, ORR	Not yet recruiting
BGB-53038-101	BGB-53038	Pan-KRASi	Ph1	NCT06585488	Solid Tumors	177	Tislelizumab Cetuximab	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Not yet recruiting
BGB-58067-101	BGB-58067	PRMT5i	Ph1	NCT06589596	Solid Tumors	92		AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Not yet recruiting

Refer to Glossary abbreviations

Phase 2 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
AMG757 20230273	Tarlatamab	DLL3xCD3	Ph2	NCT06502977	3L+ SCLC	30 (CN)		ORR	Enrolling
BGB-A317-A445-201	BGB-A445	OX40	Ph2	NCT05661955	Melanoma, UC	191	Tislelizumab	ORR	Enrolling
BGB-LBL-007-201	BGB-LBL-007	LAG3	Ph2	NCT05609370	MSS-CRC	226	Tislelizumab, Chemotherapy, Bevacizumab	PFS, AE, SAE	Enrolling
BGB-LBL-007-202	BGB-LBL-007	LAG3	Ph2	NCT06010303	1L ESCC	120	Tislelizumab, Chemotherapy	ORR	Maintenance
BGB-LC-203	BGB-A445	OX40	Ph2	NCT06029127	2L+ NSCLC	49	Chemotherapy	ORR, OS	Maintenance
ZWI-ZW25-203	Zanidatamab	HER2	Ph2	NCT04466891	2L+ BTC	100		ORR	Close-out

Refer to Glossary abbreviations

Phase 3 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
AMG757 20200041	Tarlatamab	DLL3xCD3	Ph3	NCT06211036	ES-SCLC	95 (CN)	Durvalumab	OS	Enrolling
BGB-A317-290-LTE1	BeiGene assets	Multiple	Ph3	NCT04164199	Multiple	372*	Multiple	Immune mediated adverse events	Enrolling
ZWI-ZW25-301	Zanidatamab	HER2	Ph3	NCT05152147	1L HER2+ GEA	459	Tislelizumab ± Chemotherapy	PFS, OS	Maintenance
AdvanTIG-302	Ociperlimab	TIGIT	Ph3	NCT04746924	1L NSCLC (PDL1 H)	671	Tislelizumab	OS	Maintenance
AMG757 20210004	Tarlatamab	DLL3xCD3	Ph3	NCT05740566	2L SCLC	98 (CN)		OS	Maintenance
AMG757 20230016	Tarlatamab	DLL3xCD3	Ph3	NCT06117774	LS-SCLC	77 (CN)		PFS	Maintenance
BGB-290-302	Pamiparib	PARPi	Ph3	NCT03519230	Platinum-sensitive Recurrent OC	216		PFS	Maintenance

* Currently enrolled patients, more patients may be enrolled in future
Refer to Glossary abbreviations

Full List of Commercial and Clinical Assets

Commercial		
Product	**Commercial Rights**	**Partner**
Brukinsa (zanubrunitib)	Global	-
Tevimbra (tislelizumab)	Global	-
Partruvix (pamiparib)	Global	-
Xgeva (denosumab)	China	Amgen
Blincyto (blinatumomab)	China	Amgen
Kyprolis (carfilzomib)	China	Amgen
Revlimid (lenalidomide)	China	BMS
Vidaza (azacitidine)	China	BMS
Sylvant (siltuximab)	China	EUSA Pharma
Qarziba (dinutuximab)	China	EUSA Pharma
Pobevcy (Avastin biosimilar)	China	Bio-Thera
Baituowei (goserelin microspheres for injection)	China	Luye Pharma
Tafinlar (dabrafenib)	China	Novartis
Mekinist (trametinib)	China	Novartis
Votrient (pazopanib)	China	Novartis
Afinitor (everolimus)	China	Novartis
Zykadia (ceritinib)	China	Novartis

Clinical Pipeline					
Asset	**Latest stage**	**Partner**	**Asset**	**Latest stage**	**Partner**
Sonrotoclax	Ph3	-	BGB-68501 (CDK2i)	Ph1	Ensem
Ociperlimab	Ph3	-	BG-C9074 (B7H4 ADC)	Ph1	Duality Bio
Zanidatamab	Ph3	Zymeworks/Jazz	Xaluritamig	Ph1	Amgen
Tarlatamab	Ph3	Amgen	BGB-45035 (IRAK4 CDAC)	Ph1	-
BGB-16673 (BTK CDAC)	Ph2	-	BGB-C354 (B7H3 ADC)	Ph1	-
LBL-007 (LAG-3)	Ph2	Leads Biolabs	BGB-R046 (IL-15 prodrug)	Ph1	-
BGB-A445 (OX40)	Ph2	-	BGB-B2033 (GPC3x4-1BB BsAb)	Ph1	-
BGB-21447 (BCL2i NG)	Ph1	-	BGB-3227 (MUC1xCD16A BsAb)	Ph1	-
BGB-15025 (HPK1i)	Ph1	-	BG-T187 (EGFRxMET TsAb)	Ph1	-
BGB-26808 (HPK1i 2G)	Ph1	-	BG-C137 (FGFR2b ADC) †	Ph1	-
BGB-30813 (DGKζi)	Ph1	-	BGB-53038 (PanKRASi) †	Ph1	-
BGB-A3055 (CCR8 mAb)	Ph1	-	BG-58067 (MTA Coop PRMT5i) †	Ph1	-
BGB-24714 (SMAC mimetic)	Ph1	-	BG-C477 (CEA ADC)	Ph1	-
BGB-43395 (CDK4i)	Ph1	-			

† Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

Glossary

Disease abbreviations

AML	Acute myeloid leukemia
BP-ALL	B-precursor acute lymphocytic leukemia
BTC	Biliary tract cancer
CHL	Classic Hodgkin's lymphoma
CLL	Chronic lymphocytic leukemia
dMMR	Deficient DNA mismatch repair
DLBCL	Diffuse large B-cell lymphoma
ES-SCLC	Extensive stage small cell lung cancer
ESCC	Esophageal squamous cell carcinoma
FL	Follicular lymphoma
GEA	Gastroesophageal adenocarcinoma
GC	Gastric cancer
HCC	Hepatocellular cancer
HNSCC	Head and neck squamous cell carcinoma
LS-SCLC	Limited stage small cell lung cancer
MCL	Mantle cell lymphoma
mCRPC	Metastatic castration resistant prostate cancer
MDS	Myelodysplastic syndromes
MM	Multiple myeloma
MSI-H	Microsatellite stability high
MSS CRC	Microsatellite stable colorectal cancer
MZL	Marginal zone lymphoma
Neo/adj	Neoadjuvant/adjuvant
NSCLC	Non-small cell lung cancer
NPC	Nasopharyngeal carcinoma
OC	Ovarian cancer
PMN	Primary membranous nephropathy
R/R	Relapsed or refractory
SCLC	Small cell lung cancer
SLL	Small lymphocytic lymphoma
UC / UBC	Urinary / bladder cancer
WM	Waldenström's macroglobulinemia

Other abbreviations

ADC	Antibody drug conjugate
AE	Adverse events
CDAC	Chimeric degradation activation compound
CR	Complete response
DCR	Disease control rate
DLT	Dose-limiting toxicity
DOR	Duration of response
EFS	Event free survival
LCM	Lifecycle management
LTE	Long-term extension
mAb	Monoclonal antibody
mOR	Modified overall response
MPR	Major pathological response
MTD	Maximum tolerated dose
MTx	Maintenance
ORR	Objective response rate
OS	Overall survival
PCR	Pathologic complete response
PFS	Progression-free survival
RDFE	Recommended dose for expansion
RP2D	Recommended phase 2 dose
SAE	Severe adverse events
TEAE	Treatment emergent adverse events
TN	Treatment naïve
Tsp	Tri-specific antibody
VGPR	Very good partial response

BeiGene